Business ❯ Healthcare ❯ Pharmaceuticals

Weight Loss

Eli Lilly Novo Nordisk GLP-1 Medications Wegovy GLP-1 Treatments GLP-1 Drugs Partnerships Market Trends Drug Approval GLP-1 Therapies

Novo Nordisk Pushes Back Against Lilly as Oral Wegovy Fuels U.S. Comeback

Analysts and investors will use this quarter’s results to judge whether the pill-driven momentum can make Novo’s turnaround durable.

Lilly Expands Neuroscience Pipeline With $2.8 Billion Purchase of AtaiBeckley

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Novo Nordisk Extends Weight‑Loss Lead as Amgen’s Once‑Monthly MariTide Reaches Phase 3

Novo Nordisk’s Oral Wegovy Debuts With Strong Prescriptions as BMO Stays Cautious

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results

Hims & Hers Expands Weight-Loss Offerings with New Medications